We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-3.62%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$48.3M
AUM Growth
-$10.3M
Cap. Flow
-$121K
Cap. Flow %
-0.25%
Top 10 Hldgs %
100%
Holding
8
New
Increased
Reduced
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$121K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$20.3M 41.93%
498,558
GRTS
2
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12.3M 25.42%
3,561,150
PASG icon
3
Passage Bio
PASG
$14.7M
$6.84M 14.16%
247,988
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$3.41M 7.05%
543,753
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$2.94M 6.08%
506,823
ALGS icon
6
Aligos Therapeutics
ALGS
$26.3M
$2.21M 4.58%
92,815
UTRS
7
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$374K 0.77%
83,685
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
-101,855
Closed -$121K

Similar funds

Versant Venture Management's Q4 2022 Portfolio in Review

As of Q4 2022, Versant Venture Management held 8 positions worth $48.3M, down 18% from $58.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management's Q4 2022 filing shows 1 closed position. The largest sale was Clovis Oncology, Inc., an estimated $121K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management fully exited Clovis Oncology, Inc. in Q4 2022, selling an estimated $121K.
  • Versant Venture Management's ten largest holdings make up 100% of its $48.3M portfolio in Q4 2022.
  • Versant Venture Management opened 0 new positions and closed 1 in Q4 2022.
  • Versant Venture Management's portfolio value fell 18% quarter-over-quarter to $48.3M.

Based on Versant Venture Management's 13F filing for Q4 2022, filed 9 Feb 2023.